Investment Rating - The report maintains a positive outlook on the CXO sector for the year 2026, indicating strong demand and recovery in global orders [3][26]. Core Insights - Illumina's release of the Billion Cell Atlas marks a significant advancement in life sciences, transitioning from static genomic data to a comprehensive dataset that integrates AI for drug discovery [3][8]. - Regulatory developments in China and the US are accelerating drug approval processes, with China's implementation of eCTD and the US FDA's support for Bayesian methods enhancing clinical trial efficiency [3][23]. - The CXO sector is expected to see robust growth, supported by major players like Lonza and WuXi AppTec, who are expanding capacity and reporting increased order volumes [3][26]. Summary by Sections Industry Frontiers - Illumina's Billion Cell Atlas is the largest human genome perturbation dataset to date, aimed at accelerating drug discovery through AI [3][8]. - Regulatory dynamics indicate a race for faster drug approvals, with China's NMPA adopting eCTD and the FDA endorsing Bayesian statistical methods for clinical trials [3][23]. - The global order recovery is evident, with a positive outlook for the CXO sector throughout 2026, as major companies report growth and increased demand [3][26]. Capital Trends - GSK's acquisition of RAPT Therapeutics for $2.2 billion focuses on developing an anti-IgE monoclonal antibody for food allergies, highlighting the potential in the allergy treatment market [4][31]. - Novartis has entered a $1.5 billion agreement with SciNeuro to advance a new antibody project targeting Alzheimer's disease, indicating ongoing investment in neurodegenerative treatments [4][36]. Weekly Perspective - The report emphasizes the transition to an AI-driven era in drug discovery, suggesting that previous advantages in research may diminish as the landscape evolves [5][37]. - The demand for CXO services is expected to remain strong, driven by AI-enabled drug discovery and regulatory advancements [5][38].

Core Viewpoint - The report highlights the current premium rates of AH shares, with Northeast Electric, Zhejiang Shibao, and Junda Co. leading in premium rates, while CATL, Hengrui Medicine, and China Merchants Bank are at the bottom of the list [1][2]. Premium Rate Rankings - Northeast Electric (00042) has a premium rate of 815.25%, followed by Zhejiang Shibao (01057) at 378.67% and Junda Co. (02865) at 342.63% [2]. - The lowest premium rates are recorded for CATL (03750) at -13.79%, Hengrui Medicine (01276) at -2.52%, and China Merchants Bank (03968) at -2.22% [1][2]. Deviation Values - Junda Co. (02865) has the highest deviation value at 104.89%, followed by Goldwind Technology (02208) at 23.62% and Guanghetong (00638) at 20.17% [1][2]. - The lowest deviation values are for Northeast Electric (00042) at -35.64%, Chenming Paper (01812) at -16.87%, and China Life (02628) at -15.34% [1][4]. Additional Insights - The report includes a detailed table of the top ten and bottom ten AH stocks based on premium rates and deviation values, providing a comprehensive overview of the current market situation [2][3][4].

Core Viewpoint - The company has released its 2025 performance forecast, projecting revenue of 45.46 billion yuan (+15.8%) and a net profit attributable to shareholders of 19.15 billion yuan (+102.7%), indicating better-than-expected performance [1] Revenue and Profit Forecast - For 2025, the company expects revenue of 45.46 billion yuan, with a 15.8% year-on-year growth, and a net profit of 19.15 billion yuan, reflecting a 102.7% increase [2] - The projected revenue for 2026 and 2027 is 51.55 billion yuan (+13.4%) and 58.82 billion yuan (+14.1%), respectively [2] Business Growth and Performance - The growth rate of the continuing operations revenue is forecasted at 21.4%, exceeding previous guidance of 17-18% [1] - The company anticipates that the Chemistry business will maintain rapid growth, driven by TIDES and other business segments [1] Quarterly Performance Insights - In Q4 2025, the company expects revenue of 12.6 billion yuan (+9.2%) and a net profit of 7.08 billion yuan (+142.5%) [1] - The Non-IFRS net profit margin for Q4 2025 is projected to be 35.1%, showing stability compared to Q3 2025 and significant improvement from Q4 2024 [1] Future Profitability Potential - The company expects to generate approximately 4.16 billion yuan from the sale of equity interests and 1.43 billion yuan from the sale of clinical CRO and SMO businesses in 2025 [1] - The profitability potential for 2026 remains promising due to anticipated large orders and a stable recovery in overseas demand [1]

Market Overview - The precision medicine sector experienced a decline of 1.69% on January 20, with WuXi AppTec leading the drop [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] Stock Performance - Notable gainers included: - ST Xiangxue, closing at 9.72 with a rise of 7.05% and a trading volume of 193,900 shares [1] - Zhaoli Pharmaceutical, closing at 17.50 with a rise of 3.18% and a trading volume of 270,200 shares [1] - Major decliners included: - WuXi AppTec, closing at 99.46 with a decline of 2.86% and a trading volume of 481,100 shares [2] - Guomai Technology, closing at 11.56 with a decline of 2.45% and a trading volume of 361,100 shares [2] Capital Flow - The precision medicine sector saw a net outflow of 346 million yuan from institutional investors, while retail investors had a net inflow of 400 million yuan [2][3] - Specific stock capital flows indicated: - DIAN Diagnostics had a net inflow of 62.76 million yuan from institutional investors [3] - ST Xiangxue experienced a net outflow of 22.01 million yuan from retail investors [3]

Market Overview - The Hong Kong stock market experienced fluctuations today, with all three major indices closing lower. The Hang Seng Index fell by 0.29% or 76.39 points to 26,487.51 points, with a total turnover of HKD 2,377.66 million. The Hang Seng China Enterprises Index decreased by 0.43% to 9,094.76 points, and the Hang Seng Tech Index dropped by 1.16% to 5,683.44 points [1] Blue Chip Performance - Pop Mart (09992) led the blue-chip stocks, rising by 9.07% to HKD 197.2, contributing 19.52 points to the Hang Seng Index. The company announced a share buyback of 1.4 million shares for HKD 2.51 million at prices between HKD 177.7 and HKD 181.2. Morgan Stanley noted that this buyback could attract more investors [2] - Other notable blue-chip performances included China Life (601628) (02628) up 4.31% to HKD 33.4, contributing 16.6 points, and China Resources Land (01109) up 3.71% to HKD 29.64, contributing 5.52 points. Conversely, WuXi AppTec (603259) (02359) fell by 4.13% to HKD 113.7, detracting 3.73 points, and SMIC (00981) dropped by 3.25% to HKD 74.5, detracting 18.11 points [2] Sector Highlights - The technology sector showed mixed results, with Baidu rising by 0.95% while Tencent fell over 1%. Gold stocks rebounded, with spot gold surpassing USD 4,700 for the first time, and consumer stocks gained traction due to favorable consumption policies. Notably, Pop Mart's buyback led to a price increase of over 10% [3] - Gold stocks saw a recovery, with Zijin Mining International (02259) up 5.47% to HKD 179.4, Chifeng Jilong Gold Mining (600988) (06693) up 3.6% to HKD 33.94, Shandong Gold Mining (600547) (01787) up 2.73% to HKD 43.7, and China National Gold International (600916) (02099) up 2.04% to HKD 195 [3] Real Estate Sector - The National Bureau of Statistics reported a 0.3% month-on-month decline in new residential sales prices in first-tier cities for December 2025, with the decline narrowing by 0.1 percentage points from the previous month. Shenwan Hongyuan believes that the real estate sector has undergone deep adjustments, and recent central government directives to stabilize the market may lead to positive policy changes [5] - The real estate sector showed positive performance, with China Overseas Land & Investment (00081) up 4.93% to HKD 2.13, and China Resources Land (01109) up 3.71% to HKD 29.64 [4][5] Insurance Sector - The insurance sector performed well, with China Pacific Insurance (00966) up 4.39% to HKD 23.8, China Life (02628) up 4.31% to HKD 33.4, and New China Life Insurance (601336) (01336) up 2.72% to HKD 62.35. Reports indicated that major insurance companies saw significant growth in premium income through bancassurance channels [4][5] Aviation Sector - The aviation sector continued its upward trend, with China Southern Airlines (600029) (01055) up 4.57% to HKD 6.18, China National Aviation (601111) (00753) up 3.91% to HKD 7.45, and Cathay Pacific (00293) up 1.63% to HKD 12.49. Analysts expect strong demand during the upcoming Spring Festival travel season, with improved ticket pricing and revenue management driving profitability [6] Notable Stock Movements - Youjia Innovation (02431) saw a significant increase of 7.21% to HKD 15.77 after signing a memorandum of understanding with India's Sterling Tools Ltd. to focus on the automotive market [7] - Nanshan Aluminum International (02610) reached a new high, rising 6.04% to HKD 71.95, as the company plans to initiate a 250,000-ton electrolytic aluminum project with an estimated investment of USD 436.6 million [8] - GigaDevice Semiconductor (603986) (03986) continued to rise by 5.52% to HKD 306, benefiting from a tight supply of memory chips [9] - Shanghai Petrochemical (600688) (00338) issued a profit warning, expecting a net loss of approximately RMB 1.289 billion to RMB 1.576 billion for the year ending December 31, 2025 [10]

Core Viewpoint - The report highlights the premium rates of AH shares, with Northeast Electric, Zhejiang Shibao, and Junda Co. leading in premium rates, while CATL, China Merchants Bank, and Hansoh Pharmaceutical have the lowest premium rates [1]. Premium Rate Rankings - The top three AH shares by premium rate are: - Northeast Electric (00042) with a premium rate of 815.25% - Zhejiang Shibao (01057) with a premium rate of 386.24% - Junda Co. (02865) with a premium rate of 369.87% [1]. - The bottom three AH shares by premium rate are: - CATL (03750) with a premium rate of -12.69% - China Merchants Bank (03968) with a premium rate of -0.92% - Hansoh Pharmaceutical (01276) with a premium rate of -0.12% [1]. Deviation Values - The top three shares by deviation value are: - Junda Co. (02865) with a deviation value of 138.55% - Goldwind Technology (02208) with a deviation value of 35.44% - Sanhua Intelligent Control (02050) with a deviation value of 18.71% [1]. - The bottom three shares by deviation value are: - Northeast Electric (00042) with a deviation value of -39.75% - Chenming Paper (01812) with a deviation value of -27.60% - China Life (02628) with a deviation value of -19.12% [1]. Additional Premium Rate and Deviation Data - The report includes detailed tables showing the premium rates and deviation values for various AH shares, indicating significant variations among different companies [2].

Core Viewpoint - JPMorgan Chase has reduced its stake in WuXi AppTec (603259) by approximately 2.5178 million shares at a price of around HKD 119.32 per share, totaling about HKD 300 million, resulting in a new holding of approximately 33.644 million shares, representing 6.59% of the company [1][2]. Group 1 - On January 14, JPMorgan sold 2,517,805 shares of WuXi AppTec at an average price of HKD 119.3249 per share [2]. - Following the sale, JPMorgan's remaining shares in WuXi AppTec amount to approximately 33,644,022 shares, with a holding percentage of 6.59% [1][2]. - The total cash generated from this reduction in stake is approximately HKD 300 million [2].

Core Insights - The global pharmaceutical outsourcing industry is undergoing a significant transformation focused on "quality" amid tightening regulations and operational model shifts [1] - By 2025, FDA warning letters are expected to rise to 120, a 43% increase compared to pre-pandemic levels, while the EU's GMP Annex 1 will enforce stricter standards for sterile production [1] - The CXO industry will face increased compliance costs due to heightened requirements for documentation, personnel training, and process monitoring, potentially impacting operational efficiency and production flexibility in the short term [1] Industry Challenges - Companies will need to invest more in compliance measures, which may lead to limited production capacity and operational pressures [1] - An increase in deviations and investigations could result in project delays and disruptions in client supply chains [1] Long-term Outlook - Despite short-term challenges, the industry is expected to evolve towards a model prioritizing "quality and trust" over "capacity and price," driven by regulatory changes and customer demands [1] - Leading CXO companies are proactively adapting to seize opportunities in this value reassessment wave, with WuXi AppTec establishing a strong competitive advantage through a rigorous quality system [1] Company Performance - WuXi AppTec underwent over 741 quality audits and 60 information security reviews in 2025, maintaining a 100% pass rate without major findings [2] - In March 2025, WuXi AppTec's Changzhou and Taixing facilities passed FDA inspections with "zero defects," demonstrating the effectiveness of their standardized quality system [4] - As of September 2025, WuXi AppTec's ongoing business orders reached nearly 60 billion yuan, a 41.2% year-on-year increase, highlighting that top compliance and execution capabilities drive growth [4]

Group 1 - WuXi AppTec's H-shares fell by 4.3% [1] - WuXi AppTec's A-shares declined by 3.4% [1]

Group 1 - Morgan Stanley reduced its stake in WuXi AppTec (02359) by 2,517,805 shares at a price of HKD 119.3249 per share, totaling approximately HKD 300 million [1][4] - After the reduction, Morgan Stanley's remaining shareholding is approximately 33,644,000 shares, representing a stake of 6.59% [1][4]